Table I.
Effect of treatment on blood glucose levels in all experimental groups (mmol/l, means ± SEM).
| Group | 0 week | 4 weeks | 8 weeks | 12 weeks | 16 weeks |
|---|---|---|---|---|---|
| NC | 5.82±0.12 | 5.56±0.26 | 5.23±0.16 | 5.44±0.09 | 5.47±0.14 |
| DN | 25.13±2.22a | 26.48±1.57a | 27.11±3.28a | 28.54±2.14a | 26.42±2.64a |
| DN + NR1 (low) | 24.98±1.35 | 25.73±2.33 | 26.75±2.50 | 25.38±1.79 | 25.10±2.34 |
| DN + NR1 (medium) | 25.06±2.16 | 24.96±1.89 | 23.67±1.84 | 21.43±2.17b | 18.62±1.59c |
| DN + NR1 (high) | 24.92±1.05 | 25.73±2.15 | 21.58±1.49b | 16.35±3.26c | 13.75±3.64c |
n=10 in each group,
a
P<0.01 vs. NC group at the same time point;
b
P<0.05 and
c
P<0.01 vs. DN group at the same time point. NC, normal control; DN, diabetic nephropathy; NR1, notoginsenoside R1.